PT1689712E - Derivados de 4-fenilpiperidina como inibidores da renina - Google Patents

Derivados de 4-fenilpiperidina como inibidores da renina Download PDF

Info

Publication number
PT1689712E
PT1689712E PT04798086T PT04798086T PT1689712E PT 1689712 E PT1689712 E PT 1689712E PT 04798086 T PT04798086 T PT 04798086T PT 04798086 T PT04798086 T PT 04798086T PT 1689712 E PT1689712 E PT 1689712E
Authority
PT
Portugal
Prior art keywords
compounds
formula
coronary syndrome
renin inhibitors
fibrosis
Prior art date
Application number
PT04798086T
Other languages
English (en)
Inventor
Richard Sedrani
Jurgen Klaus Maibaum
Claus Ehrhardt
Werner Breitenstein
Sellner Holger
Nils Ostermann
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Publication of PT1689712E publication Critical patent/PT1689712E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT04798086T 2003-11-26 2004-11-25 Derivados de 4-fenilpiperidina como inibidores da renina PT1689712E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52537503P 2003-11-26 2003-11-26

Publications (1)

Publication Number Publication Date
PT1689712E true PT1689712E (pt) 2009-11-25

Family

ID=34632979

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04798086T PT1689712E (pt) 2003-11-26 2004-11-25 Derivados de 4-fenilpiperidina como inibidores da renina

Country Status (15)

Country Link
US (3) US20070078164A1 (pt)
EP (1) EP1689712B1 (pt)
JP (1) JP4750712B2 (pt)
KR (1) KR20060120146A (pt)
CN (1) CN1906163A (pt)
AT (1) ATE440082T1 (pt)
AU (1) AU2004293177B2 (pt)
BR (1) BRPI0416976A (pt)
CA (1) CA2546264A1 (pt)
DE (1) DE602004022704D1 (pt)
ES (1) ES2332053T3 (pt)
PL (1) PL1689712T3 (pt)
PT (1) PT1689712E (pt)
RU (1) RU2374228C2 (pt)
WO (1) WO2005051911A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2546264A1 (en) * 2003-11-26 2005-06-09 Novartis Ag 4-phenylpiperidine derivatives as renin inhibitors
EP1786814B1 (en) 2004-08-25 2010-03-31 Actelion Pharmaceuticals Ltd. Bicyclononene derivatives as renin inhibitors
KR20130048281A (ko) * 2004-10-08 2013-05-09 노파르티스 아게 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를 위한 레닌 억제제의 용도
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
EP1707202A1 (de) * 2005-03-31 2006-10-04 Speedel Experimenta AG Organische Verbindungen
GB0508992D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
BRPI0609890A2 (pt) 2005-05-27 2010-05-04 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
AR058885A1 (es) * 2005-12-30 2008-02-27 Novartis Ag Compuestos de piperidina 3,5-sustituidos
GB0611696D0 (en) * 2006-06-13 2006-07-26 Novartis Ag Organic compounds
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
WO2008074450A2 (en) * 2006-12-20 2008-06-26 Nicox S.A. Non-peptidic renin inhibitors nitroderivatives
EP1987834A3 (en) * 2007-02-13 2008-11-19 Speedel Experimenta AG Substituted piperidines as therapeutic compounds
EP1958634A3 (en) * 2007-02-14 2008-09-24 Speedel Experimenta AG Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease
EP2527338B1 (en) 2007-06-25 2015-05-06 Novartis AG N5-(2-ethoxyethyl)-n3-(2-pyridinyl) -3,5-piperidinedicarboxamide derivatives for use as renin inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4616088A (en) * 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US5668151A (en) * 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
NZ315677A (en) * 1995-09-07 2000-02-28 F 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
AU3818900A (en) 1999-04-14 2000-11-02 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
AU2002306848A1 (en) 2001-03-23 2002-10-08 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
JP2005537822A (ja) * 2002-06-28 2005-12-15 ノバルティス アクチエンゲゼルシャフト 有機化合物の使用
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
CA2546264A1 (en) * 2003-11-26 2005-06-09 Novartis Ag 4-phenylpiperidine derivatives as renin inhibitors

Also Published As

Publication number Publication date
US20070078164A1 (en) 2007-04-05
RU2006122637A (ru) 2008-01-27
US8362040B2 (en) 2013-01-29
ES2332053T3 (es) 2010-01-25
PL1689712T3 (pl) 2010-01-29
BRPI0416976A (pt) 2007-02-21
CN1906163A (zh) 2007-01-31
CA2546264A1 (en) 2005-06-09
US20100240679A1 (en) 2010-09-23
JP2007512282A (ja) 2007-05-17
AU2004293177B2 (en) 2008-10-23
AU2004293177A1 (en) 2005-06-09
EP1689712B1 (en) 2009-08-19
EP1689712A1 (en) 2006-08-16
KR20060120146A (ko) 2006-11-24
WO2005051911A1 (en) 2005-06-09
DE602004022704D1 (de) 2009-10-01
RU2374228C2 (ru) 2009-11-27
US20080269255A1 (en) 2008-10-30
ATE440082T1 (de) 2009-09-15
US7754727B2 (en) 2010-07-13
JP4750712B2 (ja) 2011-08-17

Similar Documents

Publication Publication Date Title
TNSN06156A1 (en) Organic compounds
PT1689712E (pt) Derivados de 4-fenilpiperidina como inibidores da renina
WO2004052855A3 (en) Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052854A3 (en) Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
NO20055246L (no) Heteroaromatisk pentasyklisk forbindelse og medisinsk anvendelse derav
WO2007076367A3 (en) Rnai-mediated inhibition of rho kinase for treatment of ocular hypertension / glaucoma
YU78703A (sh) Derivati merkaptoacetilamida, postupak za njihovo pripremanje i njihova upotreba
CA2370888A1 (en) Renin inhibitors
AP2003002853A0 (en) Heterocyclic inhibitors of ERK2 and uses thereof
NO332654B1 (no) Acylerte arylsykloalkylaminer og deres anvedelse og farmasoytisk preparat inneholdende minst en slik forbindelse
SI1732534T1 (sl) Uporaba derivatov metilen amida pri kardiovaskularnih obolenjih
DE10393825D2 (de) Hemmung der Proteinkinase C Alpha zur Behandlung von Diabetes mellitus und kardiovaskulärer Erkrankungen
NO20052487L (no) 1-(4-benzyl-piperazin-1-yl)-3-fenyl-propenonderivater.
TR200103067T2 (tr) Renin inhibitörleri
WO2004012663A3 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
MX340804B (es) Compuestos inhibidores de 11 beta-hidroxiesteroide deshidrogenasa de tipo 1.
AU6066390A (en) Peptides containing diamino-glycols as transition-state mimics
NO20062527L (no) Nitrooksyderivater av antihypertensive legemidler
WO2003099822A3 (en) 1,2-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
IL164397A0 (en) 1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates forthe production thereof
WO2008097953A3 (en) Pharmaceutical compositions containing substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
NO20034412L (no) Merkaptoacetylamidderivater, fremgangsmåte for deres fremstilling og deresanvendelse
WO2024036243A3 (en) Salts of heterocyclic inhibitors of monocarboxylate transporter 4 for the treatment of disease
IL204259A (en) Use of resburicase to prepare a drug to treat or prevent heart disease or heart problems caused by previous events or blockage of blood flow to the heart